Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 10, 2001 - Issue 12
Submit an article Journal homepage
61
Views
25
CrossRef citations to date
0
Altmetric
Miscellaneous

Telomerase inhibitors for the treatment of cancer: the current perspective

Philip J Perry [email protected]
,
John RP Arnold [email protected]
&
Terence C Jenkins [email protected]
Pages 2141-2156 | Published online: 24 Feb 2005

Bibliography

  • PERRY PJ, JENKINS TC: Recent advances in the development of telomerase inhibitors for the treatment of cancer. Expert Opin. Investig. Drugs (1999) 8:1981-2008. ccA comprehensive review of strategies in thedesign and evaluation of novel antitelomerase drug-based agents for potential application in chemotherapeutic treatments.
  • KELLAND LR: Telomerase inhibitors: targeting the vulnerable end of cancer? Anti-Cancer Drugs (2000) 11:503–513.
  • LAVELLE F, RIOU J-F, LAOUI A, MAILLIET P: Telomerase: a therapeutic target for the third millennium. Grit. Revs. in Oncology/Haematology (2000) 34:111–126.
  • SHAY JW, ZOU Y, HIYAMA E, WRIGHT WE: Telomerase and cancer. Human Mel. Genet. (2001) 10:677–685.
  • BLACKBURN EH: Switching and signalling at the telomere. Cell (2001) 106:661–673.
  • PERRY PJ, JENKINS TC: DNA tetraplex-binding drugs: structure-selective targeting is critical for antitumour telomerase inhibition. Mini Revs. Med. Chem. (2001) 1:31–41.
  • CAIRNS D, ANDERSON RJ, PERRY PJ, JENKINS TC: The design of telomerase inhibitors for the treatment of cancer. Cun: Pharm. Des. (2002) in press.
  • CHEN JL, BLASCO MA, GREIDER CW: Secondary structure of vertebrate telomerase RNA. Cell (2000) 100:503–514.
  • •Phylogenetic comparison amongst 32 vertebrate telomerase RNA sequences reveals a consistent secondary structure with distinct conserved and variable regions.
  • MARTIN-RIVERA L, BLASCO MA: Identification of functional domains and dominant negative mutations in vertebrate telomerase RNA using an in vivo reconstitution system. J. Biol. Chem. (2001) 276:5856–5865.
  • GILLEY D, BLACKBURN EH: The telomerase RNA pseudoknot is critical for the stable assembly of a catalytically active ribonucleoprotein. Proc. Nati Acad. Li. USA (1999) 96:6621–6625.
  • MITCHELL JR, COLLINS K: Human telomerase activation requires two independent interactions between telomerase RNA and telomerase reverse transcriptase. Mol. Cell (2000) 6:361–371.
  • BACHAND F, AUTEXIER C: Functional regions of human telomerase reverse transcriptase and human telomerase RNA required for telomerase activity and RNA-protein interactions. Mol. Cell. Biol. (2001) 21:1888–1897.
  • BACHAND F, TRIKI I, AUTEXIER C: Human telomerase RNA-protein interactions. Nucl. Acids Res. (2001) 29:3385–3393.
  • SPERGER JM, CECH TR: A stem-loop ofTetrahymena telomerase RNA distant from the template potentiates RNA folding and telomerase activity. Biochemistry (2001) 40:7005–7016.
  • WENZ C, ENENKEL B, AMACKER M, KELLEHER C, DAMM K, LINGNER J: Human telomerase contains two co-operating telomerase RNA molecules. EMBO J. (2001) 20:3526–3534.
  • KIM MM, RIVERA MA, BOTCHKINA IL, SHALABY R, THOR AD, BLACKBURN EH: A low threshold level of expression of mutant-template telomerase RNA inhibits human tumour cell proliferation. Proc. Natl. Acad. Sri. USA (2001) 98:7982–7987.
  • ••Low-level expression of aberrant telomeresequences, due to the presence of mutant hTRs, has profound effects on proliferation in cancer cell lines.
  • VILLA R, PORTA CD, FOLINI M, DAIDONE MG, ZAFFARONI N: Possible regulation of telomerase activity by transcription and alternative splicing of telomerase reverse transcriptase in human melanoma. J. Invest. Dermatol. (2001) 116:867–873.
  • ULANER GA, HU J-F, VU TH, ORUGANTI H, GIUDICE LC, HOFFMAN AR: Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium. mt. J. Cancer (2000) 85:330–335.
  • STANTA G, BONIN S, NICCOLINI B, RACCANELLI A, BARALLE F: Catalytic subunit of telomerase expression is related to RNA component expression. FEBS Lett. (1999) 460:285–88.
  • MATTHEWS DH, SABINA J, ZUKER M, TURNER DH: Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J. Mol. Biol. (1999) 288:911–940.
  • ZUKER M, MATHEWS DH, TURNER DH: Algorithms and thermodynamics for RNA secondary structure prediction: a practical guide. In RNA Biochemistry and Biotechnology Barciszewski J, Clark BCF, (Eds.), NATO ASI series, Kluwer Academic, USA, (1999):11–43.
  • PAGE TJ, MATA JE, BRIDGE JA, SIEBLER JC, NEFF JR, IVERSON PL: The cytotoxic effects of single-stranded telomere mimics on OMA-BL1 cells. Exp. Cell Res. (1999) 252:41–49.
  • •The absence of a correlation between cytotmdcity and telomerase inhibition in OMA-BL1 cells for a series of telomere mimics highlights the gaps in current knowledge in this area.
  • LEAMAN DW, CRAMER H: Controlling gene expression with 2–5A antisense. Methods: A Companion to Meth. Enzymol. (1999) 18:252–265.
  • MUKAI S, KONDO Y, KOGA S, KOMATA T, BARNA BP, KONDO S: 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res. (2000) 60:4461–4467.
  • •Encouraging results are presented for both cultured cells and nude mice after optimisation of the 2-5A-ODN/cationic liposome ratio used for delivery. The possible involvement of caspases in apoptosis is noted.
  • KONDO Y, KOGA S, KOMATA T, KONDO S: Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Oncogene (2000) 19:2205–2211.
  • KOGA S, KONDO Y, KOMATA T, KONDO S: Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA. Gene Ther. (2001) 8:654–658.
  • KONDO Y, KOMATA T, KONDO S: Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas. mt. J. Oncol. (2001) 18:1287–1292.
  • KOMATA T, KONDO Y, KOGA S, KO SC, CHUNG LWK, KONDO S: Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53. Gene Therapy (2000) 7:2071–2079.
  • KUSHNER DM, PARANJAPE JM, BANDYOPADHYAY B et al.: 2-5A Antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells. Cyriecol. Oricol. (2000) 76:183–192.
  • TAO M, MIYANO-KURASAKI N, TAKEI K, TAKAKU H: Specific inhibition of human telomerase activity by transfection agent, FuGENE6-antisense phosphorothioate oligonucleotide complex in HeLa cells. FEBS Lett. (1999) 454:312–316.
  • TAMURA Y, TAO M, MIYANO-KURASAKI N, TAKEI K, TAKAKU H: Inhibition of human telomerase activity by antisense phosphorothioate oligonucleotides encapsulated with the transfection agent, FuGENE6, in HeLa cells. Antisense Nucl. Acid Drug Bevel. (2000) 10:87–96.
  • HERBERT BS, PITTS AE, BAKER SI et Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Nati Acad. Li. USA (1999) 96:14276–14281.
  • ••Demonstration that telomerase inhibition isof potential therapeutic use. PNA and 2'- 0-MeRNA, targeted at the template region of hTR, are shown to effectively inhibit telomerase. The telomeres of cultured cells gradually shorten and apoptosis is induced, provided that administration of an antisense agent is maintained.
  • ELAYADI AN, DEMIEVILLE A, WANCEWICZ EV, MONIA BP, COREY DR: Inhibition of telomerase by 2'-0-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells. Nucl. Acids Res. (2001) 29:1683–1689.
  • HAMILTON SE, SIMMONS CG, KATHIRIYA IS, COREY DR: Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chem. and Biol. (1999) 6:343–351.
  • ••The use of lipid-mediated antisense PNAprobing a range of sites within hTR provides early clues as to the folding of hTR.
  • SHAMMAS MA, SIMMONS CG, COREY DR, SHMOOKLER RJ:Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed cells. Oncogene (1999) 18:6191–6200.
  • YUEN AR, SIKIC BI: Clinical studies of antisense therapy in cancer. Frontiers Biosci. (2000) 5:D588–D593.
  • YOKOYAMA Y, TAKAHASHI Y, SHINORA A, WAN XY, TAKAHASHI S, NIWA K, TAMAYA T: The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity. Biochem. Biophys. Res. Commun. (2000) 273:316–321.
  • LUDWIG A, SARETZKI G, HOLM PS, TIEMANN F et al.: Ribozyme cleavage of telomerase mRNA sensitises breast cancer cells to inhibitors of topoisomerase. Cancer Res. (2001) 61:3053–3061.
  • FOLINI M, COLELLA G, VILLA R, LUALDI S, DAIDONE MG, ZAFFORONI N: Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells. j Invest. Dermatol. (2000) 114:259–267.
  • STRAHL C, BLACKBURN EH: The effects of nucleoside analogues on telomerase and telomeres in Tetrahymena. Nucleic Acids Res. (1994) 22:893–900.
  • YEGOROV YE, AKIMOV SS, AKHMALISHEVA AK et al.: Blockade of telomerase function in various cells. Anti-Cancer Dug Des. (1999) 14:305–316.
  • TENDIAN SW, PARKER WB: Interaction of deoxyguanosine nucleotide analogues with human telomerase. Mol. Pharmacol. (2000) 57:695–699.
  • FLETCHER TM, CATHERS BE, RAVIKUMAR KS, MAMIYA BM, KERWIN SM: Inhibition of human telomerase by 7-deaza-2'-deoxyguanosine nucleoside triphosphate analogues: Potent inhibition by 6-thio-7-deaza-2'-deoxyguanosine 5'-triphosphate. Bioorg. Chem. (2001) 29:36–55.
  • •Report of the most potent nucleotide-based telomerase inhibitor to date.
  • JENKINS TC: Targeting multi-stranded DNA structures. Current Med. Chem. (1999) 6:99–115.
  • SIMONSSON T: G-quadruplex DNA structures - variations on a theme. Biol. Chem. (2001) 382:621–628.
  • •Recent review of DNA tetraplexes and their likely involvement in key biological events.
  • LANE AN, JENKINS TC: Structures and properties of multi-stranded nucleic acids. Current Org. Chem. (2001) 5:845–869.
  • MARATHAS VM, BOLTON PH: Determinants of DNA quadruplex structural type: sequence and potassium binding. Biochemistry (1999) 38:4355–4364.
  • MARATHAS VM, BOLTON PH: Structures of the potassium-saturated, 2:1, and intermediate, 1:1, forms of a quadruplex DNA. Nucl. Acids Res. (2000) 28:1969–1977.
  • BASU S, SZEWEZAK AA, COCCO M, STROBEL SA: Direct detection of monovalent ion binding to a DNA G-quartet by 205T1NMR. I Am. Chem. Soc. (2000) 122:3240–3241.
  • SHI XD, FETTINGER JC, DAVIS JT: Homochiral G-quadruplexes with Ba2+ but not with 1‹.*: the cation programs enantiomeric self-recognition. I Am. Chem. Soc. (2001) 123:6738–6739.
  • MARATHIAS VM, SAWICKI MJ, BOLTON PH: 6-Thioguanine alters the structure and stability of duplex DNA and inhibits quadruplex DNA formation. Nucl. Acids Res. (1999) 27:2860–2867.
  • MEYER M, BRANDL M, SOHNEL J: Are guanine tetrads stabilised by bifurcated hydrogen bonds? J Phys. Chem. A (2001) 105:8223–8225.
  • SPACKOVA N, BERGER I, SPONER J: Structural dynamics and cation interactions of DNA quadruplex molecules containing mixed guanine/cytosine quartets revealed by large-scale MD simulations. I Am. Chem. Soc. (2001) 123:3295–3307.
  • CHOWDHURY S, BANSAL M: A nanosecond molecular dynamics study of antiparallel d(G)7 quadruplex structures: effect of the coordinated cations. _J. Biomol. Struct. Dpi. (2001) 18:647–669.
  • FED OROFF OY, SALAZAR M, HAN H et al.: NMR-based model of a telomerase-inhibiting compound bound to G-quadruplex DNA. Biochemistry (1998) 37:12367–12374.
  • KERWIN SM: G-quadruplex DNA: a targetfor drug design. Curr. Pharm. Design (2000) 6:441–471.
  • HURLEY LH, WHEELHOUSE RT, SUN D, KERWIN SM, SALAZAR M et al.: G-quadruplexes as targets for drug design. Pharmacol. Ther. (2000) 85:141–158.
  • HAN H, HURLEY LH: G-quadruplex DNA: a potential target for anti-cancer drug design. Trends Pharm. Sci. (2000) 21:136–142.
  • HAN H, CLIFF CL, HURLEY LH: Accelerated assembly of G-quadruplex structures by a small molecule. Biochemistry (1999) 38:6981–6986.
  • HAN H, BENNETT RJ, HURLEY LH: Inhibition of unwinding of G-quadruplex structures by Sgsl helicase in the presence of NN-bis [2- (1-piperidine)ethy11-3,4,9,10-perylenetetracarboxylic diimide, a G-quadruplex-interactive ligand. Biochemistry (2000) 39:9311–9316.
  • RANGAN A, FEDOROFF OY, HURLEY LH: Induction of duplex to G-quadruplex transition in the c-myc promoter region by a small molecule. j Biol. Chem. (2001) 276:4640–4646.
  • SIMONSSON T, PECINKA P, KUBISTA M: DNA tetraplex formation in the control region of c- myc. Nucleic Acids Res. (1998) 26:1167–1172.
  • TUNTIWECHAPIKUL W, LEE JT, SALAZAR M: Design and synthesis of the G-quadruplex-specific cleaving reagent perylene-EDTA4ron(II). I Am. Chem. Soc. (2001) 123:5606–5607.
  • VIALAS C, PRATVIEL G, MEUNIER B: Oxidative damage generated by an oxo-metalloporphyrin onto the human telomeric sequence. Biochemistry (2000) 39:9514–9522.
  • BENNETT M, KRAH A, WIEN F, GARMAN E et al.: A DNA-porphyrin minor-groove complex at atomic resolution: the structural consequences of porphyrin ruffling. Proc. Natl. Acad. Sci. USA (2000) 97:9476–9481.
  • HAN H, LANGLEY DR, RANGAN A, HURLEY LH: Selective interactions of cationic porphyrins with G-quadruplex structures. J. Am. Chem. Soc. (2001) 123:8902–8913.
  • ARTHANARI H, BOLTON PH: Porphyrins can catalyse the interconversion of DNA quadruplex structural types. Anti-Cancer Drug Des. (1999) 14:317–326.
  • GIBSON V, ANDERSON RJ, JENKINS TC, CAIRNS D: Synthesis of mono- and bis-substituted anthraquinones as inhibitors of human telomerase. Pharm. Pharmacol. Comm. (1999) 5:669–671.
  • CAIRNS D, MICHALITSI E, JENKINS TC, MACKAY SP: Molecular modelling and cytotoxicity of substituted anthraquinones as inhibitors of human telomerase. Bioorg. Med. Chem. (2002) 10:in press.
  • REN J, CHAIRES JB: Sequence and structural selectivity of nucleic acid binding ligands. Biochemistry (1999) 38:16067–16075.
  • READ MA, NEIDLE SS: Structural characterisation of a guanine-quadruplex ligand complex. Biochemistry (2000) 39:13422–13432.
  • READ MA, WOOD AA, HARRISON JR, GOWAN SM et al.: Molecular modelling studies on G-quadruplex complexes of telomerase inhibitors: structure-activity relationships. j Med. Chem. (1999) 42:4538–4546.
  • HARRISON RJ, GOWAN SM, KELLAND LR et al.: Human telomerase inhibition by substituted acridine derivatives. Bioorg. Med. Chem. Lett. (1999) 9:2463–2468.
  • KELLAND LR: Telomerase: biology and Phase I trials. The Lancet Oncology (2001) 2:95–102.
  • READ M, HARRISON RJ, ROMAGNOLI B, TANIOUS FA et al.: Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors. Proc. Nati Acad. Sri. USA (2001) 98:4844–4849.
  • CAPRIO V, GUYEN, BOAHEN-OPOKU Y et al.: A novel inhibitor of human telomerase derived from 10H-indolo [3,2-b]quinoline. Bioorg. Med. Chem. Lett. (2000) 10:2063–2066.
  • KOEPPEL F, RIOU J-F, LAOUI A, MAILLIET P et al.: Ethidium derivatives bind to G-quartets, inhibit telomerase and act as fluorescent probes for quadruplexes. Nucl. Acids Res. (2001) 29:1087–1096.
  • ••Rational development of novel DNAtetraplex-interactive ligands with preferential binding for high-order DNA. This strategy results in agents that display remarkable telomerase inhibitory activity.
  • MERGNY J-L, LACROIX L, TEULADE-FICHOU M-P, HOUNSOU C etal.: Telomerase inhibitors based on quadruplex ligands selected by a fluorescence assay. Proc. Nati Acad. Sci. USA (2001) 98:3062–3067.
  • •Demonstration of a correlation between telomerase inhibition and thermal stabilisation of a DNA tetraplex-ligand complex. Highly potent antitelomerase activity.
  • MERGNY J-L, MAURIZOT J-C: Fluorescence resonance energy transfer as a probe for G-quartet formation by a telomeric repeat. Chem. Bio. Chem. (2001) 2:124–132.
  • SHIN-YA K, WIERZBA K, MATSUO K-I etal.: Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. I Am. Chem. Soc. (2001) 123:1262–1263.
  • ••Report of an extremely potent and selectivenatural product inhibitor of human telomerase activity.
  • WANG Y, PATEL DJ: Solution structure of the human telomeric repeat drAG3(T2AG3)31 G-tetraplex. Structure (1993) 1:263–282.
  • ••Quality NMR structure providing a definedbasis for the design of ligands capable of inhibiting telomerase by interacting with the folded human telomeric DNA tetraplex.
  • HURLEY LH: The Frank Rose Memorial Lecture: Targeting nuclear protein complexes in cancer cells for selective cancer therapeutics. Br. j Cancer (2001) 85:S35.
  • UENO T, TAKAHASHI H, ODA M et al.: Inhibition of human telomerase by rubromycins: Implication of spiroketal system of the compounds as an active moiety. Biochemistry (2000) 39:5995–6002.
  • TOGASHI KI, KAKEYA H, MORISHITA M, SONG YX, OSADA H: Inhibition of human telomerase activity by alterperylenol. Oricol. Res. (1998) 10:449–453.
  • TOGASHI K, KO HR, AHN JS, OSADA H: Inhibition of telomerase activity by fungus metabolites CRIVI646-A and thielavin B. Biosci. Biotechnol. Biochem. (2001) 65:651–653.
  • JIN J, HAUBERG M, HEIDORN K, KLAPPER W, PARWARES CH R: Inhibition of telomerase by homoharringtonine induces apoptosis in a human Burkitt lymphoma cell line. Blood (1999) 94:384 (S1).
  • IMAD N, TAKASHI T: Inhibition of telomerase by tea catechins: A mechanism for tea anticancer and chemopreventative effects. Clin. Cancer Res. (1999) 5:496(5).
  • KU W-C, CHENG A-J, WANG T-CV: Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. Biochem. Biophys. Res. Commun. (1997) 241:730–736.
  • OGRETMEN B, SCHADY D, USTA J et al.: Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. j Biol. Chem. (2001) 276:24901–24910.
  • SASAKI S, EHARA T, SAKATA I etal.: Development of novel telomerase inhibitors based on a bisindole unit. Bioorg. Med. Chem. Lett. (2001) 11:583–585.
  • BARE LA, TRINH L, WU S, DEVLIN JJ:Identification of a series of potent telomerase inhibitors using a time-resolved fluorescence-based assay. Drug Dev. Res. (1998) 43:109–116.
  • HAYAKAWA N, NOZAWA K, OGAWA A et al.: Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Biochemistry (1999) 38:11501–11507.
  • NAASANI I, SEIMIYA H, YAMORI T, TSURUO T: FJ5002: A potent telomerase inhibitor identified by exploiting the disease-orientated screening program with COMPARE analysis. Cancer Res. (1999) 59:4004–4011.
  • ••A bioinformatics approach is adopted toidentify FJ5002 as a potent telomerase inhibitor and possible clinical candidate. Remains one of the few reports of antitelomerase-mediated cellular effects by a small-molecule inhibitor at genuinely non-toxic concentrations.
  • CAVIGIOLIO G, BENEDETTO L, BOCCALERI E, COLANGELO D, VIANO I, OSELLA D: Pt(II) complexes with different N-donor aromatic ligands for specific inhibition of telomerase. Inorg. Chim. Acta (2000) 305:61–68.
  • GALLEGO J, VARANI G: Targeting RNAwith small-molecule drugs: therapeutic promise and chemical challenge. Acc. Chem. Res. (2001) 34:836–843.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.